In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors

This study determined the in vitro functional profile of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate (OPC-14523) at rat and human serotonin (5-HT) 5-HT1A receptors and binding affinity of OPC-14523 at human frontocortical 5-HT1A receptors. OPC-14523 (1 microM) increased guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTPgammaS) binding to 5-HT1A receptor-containing regions of rat brain tissue sections (approximately 53% of the effect of 1 microM (+)8-hydroxy-2-(di-n-propylamino)tetralin ((+)8-OH-DPAT) that were blocked by the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY-100635). OPC-14523 also behaved as a partial agonist in its stimulation of [35S]GTPgammaS binding to membranes from rat hippocampus (pEC50=7.60+/-0.23, Emax=41.1% of the effect of 10 microM (+)8-OH-DPAT), human frontal cortex (pEC50=7.89+/-0.08; Emax=64% of the effect of 10 microM (+)8-OH-DPAT), and Chinese Hamster Ovary cells expressing cloned human 5-HT1A receptors (pEC50=8.0+/-0.11; Emax=85.5% of the effect of 10 microM 5-HT), and all of these effects of OPC-14523 were blocked by WAY-100635. Taken together, these data support the development of OPC-14523 as an antidepressant whose mechanism of action involves potent partial agonist activity at 5-HT1A receptors.     

Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523

The antidepressant-like activity of a novel compound, OPC-14523, was investigated in comparison with the conventional antidepressants, fluoxetine and imipramine. OPC-14523 bound with nanomolar affinities to sigma receptors (IC₅₀=47–56 nM), the 5-HT_1A receptor (IC₅₀=2.3 nM), and the 5-HT transporter (IC₅₀=80 nM). OPC-14523 inhibited the in vitro reuptake of ³H-5-HT (IC₅₀=27 nM), but it showed very weak inhibitory activity on ³H-NE and ³H-DA reuptake. OPC-14523 did not inhibit MAO A or B activities or muscarinic receptors. A single oral administration of OPC-14523 produced a marked antidepressant-like effect in the forced swimming test (FST) with rats (ED₅₀=27 mg/kg) and mice (ED₅₀=20 mg/kg) without affecting the general locomotor activity. In contrast, fluoxetine and imipramine each required at least four days of repeated dosing to show this activity. The acute activity of OPC-14523 was blocked by pretreatment with the sigma receptor antagonist NE-100 or the selective 5-HT_1A receptor antagonist WAY-100635. The induction of flat body posture by OPC-14523 was blocked by the selective 5-HT_1A receptor antagonist NAN-190, and forebrain 5-HT biosynthesis was attenuated by OPC-14523 at behaviorally effective doses. In contrast, OPC-14523, unlike fluoxetine, failed to inhibit 5-HT reuptake at oral doses below 100 mg/kg. Thus, the acute antidepressant-like action of OPC-14523 is achieved by the combined stimulation of sigma and 5-HT_1A receptors without inhibition of 5-HT reuptake in vivo.     

Effects of OPC-24439, a sigma ligand, on neuronal activities in the hippocampus

Sigma receptors in the central nervous system have been considered to play an important role in the modulation of mental diseases and memory/learning. However, the physiological function of sigma receptors still remains unknown. To elucidate physiological functions of the sigma receptors in modulation of neuronal activities, the effects of OPC-24439 (a sigma receptor ligand) on neuronal activities in hippocampal slices were studied with electrophysiological methods. Hippocampal slices (thickness ca. 450 microns) were prepared from male Wistar rats (4-7 weeks of age). In extracellular recording, population spikes in the CA1 region evoked by stimulation applied to the Schaffer collateral/commissural fibers were suppressed by OPC-24439 (1-100 microM) in a dose-dependent manner. This inhibition was antagonized by simultaneously applied haloperidol at 1 microM. In intracellular recording experiments, OPC-24439 (100 microM) did not affect the resting membrane potentials of neurons recorded. In addition, OPC-24439 had no effects on depolarization and firing induced by glutamate. These results indicate that sigma receptor activation caused suppression of neuronal activities in the hippocampus via the sigma receptors. This inhibition probably mediated via the suppression of ion channels that are not related to membrane potentials on post-synaptic neurons and/or sigma receptors on pre-synaptic neurons or interneurons.     

Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors

S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-alpha]-pyrazine (CSP-2503) is a serotonin (5-HT) receptor ligand with selectivity and high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors. CSP-2503 reduced rectal temperature and 5-HT neuronal hypothalamic activity in mice, decreased electrical activity of raphe nuclei cells in rats and blocked the enhancement of adenylate cyclase activity induced by forskolin in HeLa cells transfected with the human 5-HT1A receptor. This compound also blocked head-twitches induced by the 5-HT(2A/2C) receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI). Contractions of guinea pig ileum induced by the 5-HT3 receptor agonist 2-methyl-5-HT were prevented by CSP-2503. Moreover, it reduced the bradycardia reflex induced by 2-methyl-5-HT in anaesthetized rats. In the light/dark box and social interaction tests, CSP-2503 presented anxiolytic activity, an action shared by 5-HT1 agonists and 5-HT3 antagonists. Taken together, these results suggest that CSP-2503 is a new 5-HT1 receptor agonist with 5-HT2A and 5-HT3)receptor antagonist activities that might be useful in a number of conditions associated with anxiety.     

Interactions of GR127935, a 5-HT1B/D receptor ligand, with functional 5-HT receptors

GR127935 (N-[methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2’-methyl-4’-(5-methyl-1,2,4-oxadiazol-3-yl) [1, 1-biphenyl]-4-carboxamide hydrochloride) has been recently introduced as an experimental tool to antagonize 5-HT_1B/D receptor-mediated functional responses. The compound indeed exhibits a very high affinity and selectivity for 5-HT_1B/D binding sites and it antagonizes a number of 5-HT_1B/D receptor-mediated responses. The present experiments were performed to investigate the selectivity of GR127935 against functional responses mediated by 5-HT₁-like, ‘orphan’ 5-HT₁-like (5-ht₇?), 5-HT₂, 5-HT₃ or 5-HT₄ receptors in several invivo preparations. Intravenous (i.v.) treatment with GR127935 (300μg?kg^-1) potently antagonized decreases in total carotid blood flow as well as hypotensive responses induced by the 5-HT₁-like receptor agonist sumatriptan in rabbits. I.v. bolus injections of GR127935 (up to 500 and/or 1500μg?kg^-1) did not significantly modify 5-HT-induced: (i) tachycardia in the pig (5-HT₄ receptor-mediated) and cat (‘orphan’ 5-HT₁-like or, perhaps, 5-ht₇ receptor-mediated); (ii) depressor effects in the rat and cat (‘orphan’ 5-HT₁-like or 5-ht₇ receptor-mediated); (iii) vonBezold-Jarisch reflex in the rat or the early phase of the urinary bladder contraction in the cat (both 5-HT₃ receptor-mediated). In contrast, high doses (500-1500μg?kg^-1) of GR127935 suppressed 5-HT-induced pressor responses in the rat and cat and urinary bladder contractions (secondary phase) in the cat as well as the DOI ((±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride)-induced pressor responses in the rat, which are all mediated by 5-HT_2A receptors. In conclusion, the present study demonstrates that GR127935 is a selective 5-HT_1B/D receptor antagonist devoid of interactions at ‘orphan’ 5-HT₁-like (5-ht₇?), 5-HT₃ and 5-HT₄ receptors. However, GR127935 possesses a moderate 5-HT_2A receptor blocking property, which is consistent with its binding profile (pK_i: 7.4). Lastly, in view of the potent antagonist action of GR127935, the sumatriptan-induced hypotension in rabbits seems to be mediated by 5-HT_1B/D receptors.     

8-OH-DPAT-induced effects on prepulse inhibition: pre- vs. post-synaptic 5-HT1A receptor activation

Prepulse inhibition (PPI) is a measure of sensorimotor gating that is deficient in schizophrenia. In rats, administration of the serotonin-1A (5-HT1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), causes a disruption of PPI. It is unclear whether this effect is due to the activation of pre- or post-synaptic 5-HT1A receptors, however pre-synaptic receptors located in the dorsal raphe nucleus (DRN) may play a role. Our previous research showed that castrated rats have a reduced sensitivity to 8-OH-DPAT-induced disruptions of PPI. Therefore, in , male Sprague-Dawley rats were sham-operated or castrated and micro-injected with 8-OH-DPAT directly into the DRN. In , male rats were sham-operated or received a selective serotonergic, 5,7-dihydroxytryptamine lesion of the DRN. 8-OH-DPAT was injected subcutaneously in these rats. In both sham-operated and castrated rats, a micro-injection of 8-OH-DPAT into the DRN did not disrupt PPI. Instead, in castrated rats, 8-OH-DPAT treatment tended to increase PPI. A DRN lesion caused a significant reduction in 5-HT content in the frontal cortex (70% reduction), striatum (69%) and ventral hippocampus (76%). In both sham-operated and DRN-lesioned rats, systemic 8-OH-DPAT significantly disrupted PPI. Taken together, these data suggest that the disruption of PPI observed in rats with systemic 8-OH-DPAT treatment is predominantly due to an activation of post-synaptic, rather than pre-synaptic, 5-HT1A receptors.     

Chronic rTMS induces subsensitivity of post-synaptic 5-HT1A receptors in rat hypothalamus

Chronic administration of several antidepressants, notably the selective serotonin re-uptake inhibitors (SSRIs) induces sub-sensitivity of post-synaptic 5-HT1A receptors in the hypothalamus. Chronic repetitive transcranial magnetic stimulation (rTMS) is a form of treatment for depression which is often compared to electroconvulsive shock therapy (ECT). rTMS was applied to rats either on a single occasion (acute) or daily for 8 d (chronic). Twenty-four hours after the last treatment, the rats were injected with saline or 8-OH-DPAT (50 microg/kg). The rats were killed 20 min later and trunk blood taken for measurement of corticosterone and ACTH levels. Chronic rTMS did not affect basal corticosterone or ACTH levels but significantly blunted the responses to 8-OH-DPAT, while acute rTMS had no effect on either basal or 8-OH-DPAT-stimulated responses. In common with several other antidepressant treatments, chronic rTMS reduces the sensitivity of post-synaptic 5-HT1A receptors in the hypothalamus. This effect may be significant in relation to the therapeutic mechanism of rTMS.     

Evidence that blockade of post-synaptic 5-HT1 receptors elicits feeding in satiated rats

The effects of nine central 5-HT antagonists on food intake in free feeding male rats were examined. The 5-HT₂ antagonists ritanserin and ketanserin and the selective 5-HT₃ antagonists ICS 205-930 and MDL 72222 had no effect on food intake. In contrast, the non-selective 5-HT antagonists metergoline, methiothepin, mesulergine, mianserin and methysergide (all of which have high affinity for various 5-HT₁ receptor subtypes), dose-dependently increased food intake during a 4-h daytime test. Furthermore, metergoline dose dependently increased food intake over a 24-h period. Suprisingly, mesulergine decreased food intake over a 24-h period at the same doses that increased daytime food intake. This may indicate that the increase in daytime feeding produced by mesulergine is a non-specific response. Although the antagonists used have varying degrees of selectivity for 5-HT receptor subtypes, the pattern of results suggests that postsynaptic 5-HT₁ receptors (possibly of the 5-HT_1C type) play an important role in the control of feeding in rats.     

Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats

The effect in rats of chronic treatment with two specific 5-HT reuptake inhibitors (SSRI) with antidepressant properties, citalopram (10 mg/kg, i.p. twice a day for 14 days, one day washout) and fluoxetine (15 mg/kg, p.o. twice a day for 21 days, 7 days washout), was evaluated on some mechanisms involved in central 5-HT neurotransmission. No adaptive modifications of brain 5-HT uptake (sites) were found by measuring functional [³H]5-HT uptake and [³H]citalopram binding in cortical and hippocampal synaptosomes, and by [³H]citalopram binding autoradiography in the raphe nuclei (5-HT cell bodies) and the ventral tegmental area (5-HT axonal pathway). Chronic treatments had no effect on presynaptic 5-HT_1B autoreceptors, functionally evaluated by measuring 5-HT_1B-mediated inhibition of depolarization-induced [³H]5-HT release from cortical and hippocampal synaptosomes. Chronic citalopram or fluoxetine did not significantly affect the binding of [³H]BRL-43694 to 5-HT₃ receptors in the rat brain cortex. Citalopram had no effect on [¹²⁵I]SB-207710 binding to 5-HT₄ receptors, measured by autoradiography in the substantia nigra. Negative results, such as those reported in the present study, could be due to a number of variables including the animal species, the treatment schedule or the brain areas considered, thus explaining the differences from some previous reports of significant effects of SSRI. However, our negative data are in agreement with many other published studies, suggesting that adaptive modifications of brain 5-HT transporters, terminal 5-HT_1B receptors, 5-HT₃ and 5-HT₄ receptors may not be a general effect induced by all SSRI. Received: 9 December 1996 / Accepted: 1 March 1997     

5-HT1 receptors

Among the seven classes of serotonin (5-hydroxytryptamine, 5-HT) receptors which have been identified to date, the 5-HT(1) class is comprised of five receptor types, with the 5-HT(1A), 5-HT(1B) and 5-HT(1D) characterized by a high affinity for 5-carboxamido-tryptamine, the 5-HT(1E) and 5-HT(1F) characterized by a low affinity for this synthetic agonist, and all five having a nanomolar affinity for the endogenous indolamine ligand. The genes encoding 5-HT(1) receptors have been cloned in both human and rodents, allowing the demonstration that they all belong to the G-protein-coupled receptor super-family with the characteristic 7 hydrophobic (transmembrane) domain-containing amino acid sequence. All the 5-HT(1) receptor types actually interact with G alpha i/G alpha o proteins to inhibit adenylyl cyclase and modulate ionic effectors, i.e. potassium and/or calcium channels. Probes derived from the knowledge of amino acid sequence of the receptor proteins and of nucleotide sequence of their encoding mRNAs allowed the mapping of all the 5-HT(1) receptor types in the central nervous system and other tissues. For the last twenty years, both pharmacological investigations with selective agonists and antagonists and phenotypical characterization of knock-out mice have been especially informative regarding the physiological implications of 5-HT(1) receptor types. This research ends notably with the development of triptans, whose agonist activity at 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptors underlies their remarkable efficacy as antimigraine drugs. Clear-cut evidence of the implication of 5-HT(1) receptors in anxiety- and depression-like behaviours and cognitive performances in rodents should hopefully promote research toward development of novel drugs with therapeutic potential in psychopathological and dementia-related diseases.     

Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors

Summary A molecular structural criterion of ligand selectivity for the 5-HT₂ versus 5-HT_1C receptor was hypothesized on the basis of radioligand binding data. Despite the large number of compounds which have been tested at both receptors, analysis of published data led to the identification of only five agents which are greater than 10-fold selective for the 5-HT₂ versus the 5-HT_1C receptor. Comparison of the two-dimensional structures revealed that, although these five compounds represent three distinct structural classes, they share a common structural feature located in the region hypothesized to be involved in receptor binding: a carbonyl or carboxyl oxygen interposed spatially between an aromatic ring and nitrogen atom. This structural feature was used to predict the relative selectivity of compounds that had not previously been analyzed at both the 5-HT₂ and 5-HT_1C receptors.All six drugs tested which contain the identified reactive carbonyl or carboxyl group were found to be selective for the 5-HT₂ versus the 5-HT_1C receptor with selectivity ratios ranging from 26 to 380. By contrast, three agents which are structurally similar but do not contain the reactive carbonyl or carboxyl group displayed equally high affinity for both receptor binding sites. Since the physiological roles of the 5-HT₂ and 5-HT_1C receptor are markedly different, it would be of potential clinical and scientific value to utilize this molecular structural feature to further identify chemical compounds which would selectively interact with only one of the two receptors. Send offprint requests to S. J. Peroutka at the current address     

Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors

The serotonin reuptake inhibitor, fluoxetine (10.0 mg/kg, s.c.), elicited penile erections in rats. Selective blockade of 5-HT_1A autoreceptors with WAY 100,635 ((N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl) cyclo-hexanecarboxamide) (0.16 mg/kg, s.c.), or of 5-HT_1B autoreceptors with GR 127,935 (N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide) (2.5 mg/kg, s.c.), slightly (1.5- to 2-fold) increased fluoxetine-induced penile erections. However, conjoint administration of WAY 100,635 and GR 127,935 markedly (5-fold) potentiated induction of penile erections by fluoxetine. Penile erections were abolished by the novel 5-HT_2C receptor antagonist, SB 206,553 (5 methyl-1-(3-pyridil-carbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole). These data provide functional evidence for redundancy in autoreceptor control of 5-HT release. Combined blockade of 5-HT_1A and 5-HT_1B autoreceptors markedly enhances the actions of serotonin reuptake inhibitors. © 1997 Elsevier Science B.V. All rights reserved.     

Interaction of the alpha-adrenoceptor agonist oxymetazoline with serotonin 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors.

Oxymetazoline was recognized with nanomolar affinity by 5-HT1A, 5-HT1B and 5-HT1D binding sites and mimicked the effects of 5-hydroxytryptamine with about the same potency and intrinsic activity as the endogenous amine in the corresponding functional tests. At 5-HT1C receptors, oxymetazoline behaved as a mixed agonist-antagonist. Clonidine had minimal activity. Methiothepin antagonized the effects of oxymetazoline (7.4 less than pKB less than 8.8). Thus, oxymetazoline is a full and potent agonist at 5-HT1A, 5-HT1B and 5-HT1D receptors and a partial agonist at 5-HT1C receptors.     

Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

Summary The effects of several putative 5-HT₁ receptorsubtype selective ligands were investigated in biochemical models for 5-HT_1A, 5-HT_1B, and 5-HT_1D receptors (inhibition of forskolin-stimulated adenylate cyclase activity in calf hippocampus, rat and calf substantia nigra, respectively) and 5-HT_1C receptors (stimulation of inositol phosphates production in pig choroid plexus). Following compounds were studied: 5-HT (5-hydroxytryptamine), TFMPP (1-(mtrifluoromethylphenyl)piperazine), mCPP (1-m-chlorophe-nyl)piperazine, 1 CGS 12066 (7-trifluoromethyl-4-(4-methyl1-piperazinyl)-pyrrolo[1,2-a]quinoxaline 1), isamoltane (CGP 361A, 1-(2-(1-pyrrolyl)-phenoxy)-3-isopropylamino-2-propranol), quipazine, 1-NP (1-(1-naphthyl)piperazine), and PAPP (LY165163, 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)-piperazine). Among reported 5-HT_1B receptor selective drugs, TFMPP had similar potency at 5HT_1A, 5-HT_1B and 5-HT_1C receptors, mCPP did not separate between 5-HT_1B and 5-HT_1C receptors, CGS 12066 was equipotent at 5-HT_1B and 5-HT_1D receptors, and isamoltane was only slightly 5-HTIB versus 5-HT_1A selective. Quipazine showed equal potency at 5-HTIB and 5-HT_1C receptors and 1-NP did not discriminate between the four receptor subtypes. PAPP described as 5-HT_1A receptor selective, was equally potent at 5-HT_1A and 5-HT_1D receptors. The potencies determined in second messenger studies were in good agreement with the affinity values determined in radioligand binding studies. Thus 5-HT_1A, 5-HT_1B, 5-HT_1C and 5-HT_1D receptors have different pharmacological profiles as predicted from radioligand binding studies. Despite claims to the contrary, none of the tested compounds had actual selectivity for a given 5-HT₁ receptor subtype. Of interest were the properties of several of these drugs, which behaved as agonists at some receptors and as antagonists at others (e. g. quipazine, 1-NP, PAPP and isamoltane). Send offprint requests to D. Hoyer at the above address     

Effects of 5-HT1 and 5-HT2 serotonin receptors on anxiety- and depression-like behavior in female rats

The influence of the chronic (14-day) administration of 5-HT1A receptor agonist 8-OH-DPAT (0.05 mg/kg, s.c.) and 5-HT2B/2C receptor agonist m-CPP (0.5 mg/kg, i.p.) on the anxiety- and depression-like behavior has been studied in adult female rats during key phases of the ovarian cycle. The chronic administration of m-CPP at the estrous phase produced an anxiolytic effect, while at the proestrous phase, the same drug produced an anxiogenic effect. At the same time, both 8-OH-DPAT and m-CPP exhibited pronounced antidepressant effect irrespective of the ovarian cycle phase.     

MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors

In receptor binding assays (+/-)MDL 72832, 8-[4-(1,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspiro++ +[4,5] decane-7,9-dione, was a potent (pIC50 9.1), selective and stereospecific ligand for central 5-HT1A recognition sites. In functional tests, (+/-)MDL 72832 and its S(-) and R(+) enantiomers blocked stereoselectively the 8-OH-DPAT-induced neuronal inhibition of the transmurally stimulated guinea-pig ileum and the cardiovascular effects of 8-OH-DPAT in anaesthetized rats. In contrast, (+/-)MDL 72832 and its enantiomers were exclusively '8-OH-DPAT-like' in their ability to fully and stereoselectively generalize to the 8-OH-DPAT discriminative stimulus and, in reserpinised rats, to induce forepaw treading and flat body posture. These results characterize (+/-)MDL 72832 as a potent, stereoselective ligand with mixed agonist and antagonist properties at central and peripheral 5-HT1A receptors. The similar stereoselective requirements for the recognition site and functional effects provides compelling evidence that the 5-HT1A recognition site is indeed a functional receptor.     

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist

Background and purpose:

Activation of post-synaptic 5-HT_1A receptors may provide enhanced therapy against depression. We describe the signal transduction profile of {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599, a novel 5-HT_1A receptor agonist.

Experimental approach:

{"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 was compared with a chemical congener, {"type":"entrez-nucleotide","attrs":{"text":"F13714","term_id":"747841","term_text":"F13714"}}F13714, and with (+)8-OH-DPAT in models of signal transduction in vitro and ex vivo.

Key results:

{"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 was highly selective for 5-HT_1A receptors in binding experiments and in [³⁵S]-GTPγS autoradiography of rat brain, where {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 increased labelling in regions expressing 5-HT_1A receptors. In cell lines expressing h5-HT_1A receptors, {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 more potently stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, compared with G-protein activation, internalization of h5-HT_1A receptors or inhibition of cAMP accumulation. {"type":"entrez-nucleotide","attrs":{"text":"F13714","term_id":"747841","term_text":"F13714"}}F13714, (+)8-OH-DPAT and 5-HT displayed a different rank order of potency for these responses. {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 stimulated [³⁵S]-GTPγS binding more potently in frontal cortex than raphe. {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599, unlike 5-HT, more potently and efficaciously stimulated G_αi than G_αo activation. In rat prefrontal cortex (a region expressing post-synaptic 5-HT_1A receptors), {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 potently activated ERK1/2 phosphorylation and strongly induced c-fos mRNA expression. In contrast, in raphe regions (expressing pre-synaptic 5-HT_1A receptors) {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 only weakly or did not induce c-fos mRNA expression. Finally, despite its more modest affinity in vitro, {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 bound to 5-HT_1A receptors in vivo almost as potently as {"type":"entrez-nucleotide","attrs":{"text":"F13714","term_id":"747841","term_text":"F13714"}}F13714.

Conclusions and implications:

{"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 showed a distinctive activation profiles for 5-HT_1A receptor-mediated signalling pathways, unlike those of reference agonists and consistent with functional selectivity at 5-HT_1A receptors. In rat, {"type":"entrez-nucleotide","attrs":{"text":"F15599","term_id":"1130739","term_text":"F15599"}}F15599 potently activated signalling in prefrontal cortex, a feature likely to underlie its beneficial effects in models of depression and cognition.     

Serotonin 5-HT3, 5-HT4, and 5-HT-M receptors

Serotonin (5-hydroxytryptamine [5-HT]) receptors can be classified either pharmacologically, into 5-HT1, 5-HT2, 5-HT3 and 5-HT4 receptors, or functionally, into G-protein-coupled receptors (5-HT1, 5-HT2, and 5-HT4) and ligand-gated ion channels (5-HT3). This article concentrates on the pharmacology, distribution, receptor-effector coupling, possible subtypes, and species differences of 5-HT3 receptors, which are equivalent to Gaddum and Picarelli's 5-HT-M receptor. Also presented here are some of the prominent features of the recently characterized 5-HT4 receptor. Although pharmacologic similarities have been suggested between 5-HT-M and 5-HT4 receptors (some potent 5-HT3 antagonists are active, with lower potency, at 5-HT4 receptors), it is clear that 5-HT4 receptors are different from 5-HT-M receptors.     

Effects of cold stress on some 5-HT1A, 5-HT1C and 5-HT2 receptor-mediated responses.

The purpose of the present study was to analyze the influence of stress (24-h cold exposure) on presynaptic 5-HT1A receptors, and on postsynaptic 5-HT1A, 5-HT1C and 5-HT2 receptors. Cold exposure for 24 h affected neither pargyline-induced decreases in 5-hydroxyindoleacetic acid (5-HIAA) levels in midbrain and rest of brain, nor plasma glucose and corticosterone levels. Treatment with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.5-1 mg/kg), 3-5 h after the end of cold exposure triggered less intense flat body posture and forepaw treading in cold-exposed rats than in controls. On the other hand, 15- and 30-min plasma glucose responses to 8-OH-DPAT (0.25-0.5 mg/kg, 3-5 h after cold) or to the alpha 2-adrenoceptor agonist, clonidine (0.025 mg/kg), were not affected by cold, while the 15-min, but not the 30 min, plasma corticosterone response to 8-OH-DPAT was slightly amplified in cold-exposed rats. Cold exposure affected neither the inhibitory effect of 8-OH-DPAT (0.25-0.5 mg/kg, 3-5 h after cold) on midbrain 5-HIAA levels, nor the hypothermic effect of 8-OH-DPAT (0.5-1 mg/kg, 3-5 h after cold). Lastly, the hypoactivity elicited by the 5-HT1C receptor agonist, m-chlorophenyl-piperazine (1.5-3 mg/kg, 3-5 h after cold), or head shakes elicited by the 5-HT2 receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (1-2 mg/kg, 3-5 h after cold), were of similar intensities in control and in cold-exposed rats.